Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Head and Neck Cancer Clinical Trial

Official title:

Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00394147
• Other study ID #: FER-HN-003
• Status: Terminated
• Phase: Phase 2
• Start date: October 2006
• Est. completion date: December 2009

Study information

• Verified date: July 2022
• Source: Fox Chase Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.

Description:

This research study is being done because we have not yet been able to find the best treatment for recurrent or advanced head and neck cancer (SCCHN). Pemetrexed and gemcitabine have helped fight against SCCHN when each was given by itself. This study is different from others because it tests these two drugs together, which has not been tried before in patients with SCCHN. We will see how well these drugs can work to help to control or shrink your cancer.

We also want to find out what effects (good and bad) gemcitabine and pemetrexed have on you and your head and neck cancer. We do not know if these drugs will help you. Your cancer might get better or it might get worse. It might not have any effect on your condition. We can use what we learn from this research study to help other people with the same cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: December 2009
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of squamous cell cancer of the head and neck - unresectable or metastatic. Must have measurable disease by RECIST.

• Karnofsky performance status greater than or equal to 60%

• Up to one prior systemic chemotherapy, immunotherapy allowed in the advanced or metastatic setting. This does not include prior chemotherapy, immunotherapy used with radiotherapy (ie concurrent with radiation therapy or as and induction regimen pror to definitive radiation therapy).

• At least 4 weeks from prior radiation or chemotherapy, must have recovered from all acute effects of treatment.

• Adequate organ and marrow function

• Negative pregnancy test. Agree to use birth control during and for 3 months after last dose of study drug.

• At least 18 years of age.

• Sign an informed consent and HIPAA consent.

• Must be able to take and absorb enteral medication.

Exclusion Criteria:

• Serious concomitant systemic disorder that would compromise safety or ability to complete study.

• Prior treatment with gemcitabine or pemetrexed within the previous year, unless used concurrently with radiation therapy.

• Pregnancy or breastfeeding.

• Symptomatic or uncontrolled brain mets. If treated, must be off steroids for at least 2 weeks.

• Inability or unwilling to take folic acid, vitamin B12, or dexamethasone.

• Treatment within last 30 days with a drug that has not received regulatory approval for any indication.

• Inability to interrupt and NSAID or salicylate with a long half-life (piroxicam or nabumetone) for a 5 day period.

• Presence of clinically relevant third space fluid that cannot be controlled by drainage or other procedure prior to study entry.

• Active, concurrent, invasive malignancy requiring ongoing treatment.

• Corticosteroids impermissible unless for adrenal failure, septic shock or as temporizing measure for symptomatic pain, breathing, or rash.

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• pemetrexed
pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
• gemcitabine
gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle

Locations

Country	Name	City	State
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Fox Chase Cancer Center	Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	1 year
Secondary	Time to Progression	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	1 year
Secondary	Overall Survival		1 year

External Links

•   Related Info